Summary
Understand the prospects for this US$24 billion market.
- Unique market share and sales forecasts by product to 2012.
- A comprehensive examination of four major oncology therapy areas.
- Critical SWOT analyses of current and upcoming products.
This 325+ page market analysis provides a unique examination of four key oncology therapy areas:
Breast Cancer
Focusing on the changes in the gold standard, the impact of novel therapies on treatment and the new drugs in development.
Non-Small Cell Lung Cancer
Focusing on the launch of novel therapies into the arena: are they dramatically changing the way NSCLC is treated?
Colorectal Cancer
Focusing on the evolution of new treatment regimes, the development of new formulations and advances in cancer vaccines.
Prostate Cancer
Focusing on current hormonal therapies, the treatment of HRPCA and improvements in screening.
For each therapy area the report provides:
Comprehensive Overview
Patient statistics
Incidence;
Diagnosis and treatment rates.
Growth drivers
Risk factors (genetics, age, sex etc);
Stage of the disease;
Medical guidelines;
Unmet clinical need;
Screening programmes.
Current treatments
SWOT of drugs used and companies involved;
Summary of recent ASCO data (May 2005)
Highlight where and why there is still an unmet clinical need;
Sales forecasts by product 2004-2012.
Drugs in Phase II/III development
Focus on new classes of drugs and companies involved;
Sales forecasts by product (year of launch to 2012).
An overview of the value of the oncology market
Global sales;
Sales growth to 2012.
Overall conclusions
A summary of the areas of unmet clinical need and growth opportunities;
Who the major players are now and in the future.
|
